Sio Capital Management LLC recently announced the acquisition of new stake in Bionano Genomics Inc. (NASDAQ:BNGO). This fresh investment now brings its stake to 1.84% valued currently at $1.22 million. In addition, Bank Julius Bär & Co. AG raised its holdings by 0.3 million to 0.75 million shares. And The Vanguard Group, Inc. has lifted its position by 76.18% or 0.15 million shares – to 0.35 million shares.

With over 8.52 million Bionano Genomics Inc. (BNGO) shares trading Monday and a closing price of $0.61 on the day, the dollar volume was approximately $5.2 million. The shares have shown a negative weekly performance of -0.93% and its price on 08/31/20 lost nearly -1.84%. Currently, there are 138.48M common shares owned by the public and among those 136.15M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for BNGO have a consensus price objective of $1.55. The analysts have set the share’s price value over the next 12 months at a high of $2.00 and a low of $1.15 should the stock experience a downside. Incidentally, analysts’ outlook for the Bionano Genomics Inc. stock is 1.70 for the next 12 months. But an upside of 69.5% will see the stock hit the forecast high price target while mean target price for the stock is $1.50.

Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 54,500 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in Bionano Genomics Inc. are Vanguard Extended Market Index Fu, Fidelity Comwlth. Tr. – Nasdaq Co, and Fidelity Extended Market Index Fu. Vanguard Extended Market Index Fu owns 0.35 million shares of the company’s stock, all valued at over $0.28 million. Fidelity Comwlth. Tr. – Nasdaq Co bought 604.0 shares to see its total holdings expand to 0.21 million shares valued at over $0.17 million and representing 0.25% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.13% of the shares outstanding.

Shares of Bionano Genomics Inc. (NASDAQ: BNGO) opened at $0.60, down -$0.02 from a prior closing price of $0.62. However, the script later closed the day at $0.61, down -1.84%. The company’s stock has a 5-day price change of -0.93% and 23.57% over the past three months. BNGO shares are trading -50.92% year to date (YTD), with the 12-month market performance down to -59.15% lower. It has a 12-month low price of $0.25 and touched a high of $4.70 over the same period. Currently, 8.52 million shares have been traded, compared to an average intraday trading volume of 23.45 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -15.65%, -5.84%, and -17.33% respectively.

Institutional ownership of Bionano Genomics Inc. (NASDAQ: BNGO) shares accounts for 3.50% of the company’s 138.48M shares outstanding. Mutual fund holders own 3.79%, while other institutional holders and individual stakeholders account for 4.83% and 0.82% respectively.

It has a market capitalization of $85.60M. The earnings-per-share (ttm) stands at -$1.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.03% over the week and 8.32% over the month.

Analysts forecast that Bionano Genomics Inc. (BNGO) will achieve an EPS of -$0.05 for the current quarter, -$0.06 for the next quarter and -$0.2 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.06 while analysts give the company a high EPS estimate of -$0.04. Comparatively, EPS for the current quarter was -$0.59 a year ago. Earnings per share for the fiscal year are expected to decrease by -8.20%, and 39.40% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Bionano Genomics Inc. (BNGO) as a “Strong Buy” at a consensus score of 1.70. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the BNGO, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on April 08, 2020, with the firm’s price target at $1.50.